JP2019194236A5 - - Google Patents

Download PDF

Info

Publication number
JP2019194236A5
JP2019194236A5 JP2019127476A JP2019127476A JP2019194236A5 JP 2019194236 A5 JP2019194236 A5 JP 2019194236A5 JP 2019127476 A JP2019127476 A JP 2019127476A JP 2019127476 A JP2019127476 A JP 2019127476A JP 2019194236 A5 JP2019194236 A5 JP 2019194236A5
Authority
JP
Japan
Prior art keywords
compound
salt
compound according
group
compound selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019127476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019194236A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019194236A publication Critical patent/JP2019194236A/ja
Publication of JP2019194236A5 publication Critical patent/JP2019194236A5/ja
Priority to JP2022041396A priority Critical patent/JP7375072B2/ja
Pending legal-status Critical Current

Links

JP2019127476A 2014-09-17 2019-07-09 Mk2阻害剤およびその使用 Pending JP2019194236A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022041396A JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017515845A Division JP6556225B2 (ja) 2014-09-17 2015-09-16 Mk2阻害剤およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022041396A Division JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Publications (2)

Publication Number Publication Date
JP2019194236A JP2019194236A (ja) 2019-11-07
JP2019194236A5 true JP2019194236A5 (enExample) 2019-12-19

Family

ID=55454109

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515845A Active JP6556225B2 (ja) 2014-09-17 2015-09-16 Mk2阻害剤およびその使用
JP2019127476A Pending JP2019194236A (ja) 2014-09-17 2019-07-09 Mk2阻害剤およびその使用
JP2022041396A Active JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017515845A Active JP6556225B2 (ja) 2014-09-17 2015-09-16 Mk2阻害剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022041396A Active JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Country Status (30)

Country Link
US (5) US9458175B2 (enExample)
EP (2) EP3912981A1 (enExample)
JP (3) JP6556225B2 (enExample)
KR (1) KR102457848B1 (enExample)
CN (1) CN106998692B (enExample)
AU (1) AU2015317741B2 (enExample)
BR (1) BR112017005266B1 (enExample)
CA (1) CA2961607C (enExample)
CL (1) CL2017000576A1 (enExample)
CO (1) CO2017003279A2 (enExample)
CY (1) CY1124215T1 (enExample)
DK (1) DK3193611T3 (enExample)
EA (1) EA037299B1 (enExample)
EC (1) ECSP17023281A (enExample)
ES (1) ES2874561T3 (enExample)
HR (1) HRP20210529T1 (enExample)
HU (1) HUE054347T2 (enExample)
IL (1) IL251051B (enExample)
LT (1) LT3193611T (enExample)
MA (1) MA40534B1 (enExample)
MX (2) MX373341B (enExample)
PL (1) PL3193611T3 (enExample)
PT (1) PT3193611T (enExample)
RS (1) RS62017B1 (enExample)
SA (1) SA517381115B1 (enExample)
SG (2) SG10201902326XA (enExample)
SI (1) SI3193611T1 (enExample)
SM (1) SMT202100311T1 (enExample)
TW (1) TWI744217B (enExample)
WO (1) WO2016044463A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
BR112017005266B1 (pt) 2014-09-17 2022-11-01 Celgene Car Llc Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
MX387359B (es) * 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170199A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Forms and compositions of a mk2 inhibitor
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
CA3114883A1 (en) * 2018-10-02 2020-04-09 Disc Medicine, Inc. Matriptase 2 inhibitors and uses thereof
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
EP4103186A4 (en) * 2020-02-14 2024-03-06 Salk Institute for Biological Studies MONOTHERAPIES AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
WO2022020562A1 (en) * 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
WO2022104097A2 (en) * 2020-11-12 2022-05-19 Akttyva Therapeutics, Inc. Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders
CN116670142A (zh) * 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
KR20240134978A (ko) 2022-01-14 2024-09-10 상하이 한서 바이오메디컬 컴퍼니 리미티드 피리딘 함유 폴리시클릭 유도체, 이의 제조 방법 및 용도
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
EP4608401A2 (en) * 2022-10-27 2025-09-03 Bristol-Myers Squibb Company Mk2 inhibitors and uses thereof
WO2024167950A1 (en) * 2023-02-07 2024-08-15 Celgene Corporation Compounds and compositions useful as degraders of mk2 kinase
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
WO2025002076A1 (zh) * 2023-06-26 2025-01-02 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
SG159528A1 (en) 2005-02-04 2010-03-30 Senomyx Inc Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
CA2693904A1 (en) 2007-07-16 2009-01-22 Novartis Ag Heterocyclic compounds useful as mk2 inhibitors
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
NZ624345A (en) 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
ES2742261T3 (es) * 2011-04-15 2020-02-13 Hivih Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
US10934487B2 (en) 2012-02-22 2021-03-02 Merck Patent Gmbh Liquid crystalline medium
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
EA201590644A1 (ru) * 2012-09-24 2015-09-30 Клермонт Спиде Способ и система с управляемыми мобильным отправителем доступом к данным и удалением данных
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Gsk3阻害剤と抗dr5抗体の組み合わせ
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CA2908098A1 (en) * 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
BR112017005266B1 (pt) 2014-09-17 2022-11-01 Celgene Car Llc Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende
CN107406489A (zh) 2015-01-08 2017-11-28 莫伊莱麦屈克斯公司 Mk2抑制剂肽的制剂
MX387359B (es) 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
WO2018170199A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Forms and compositions of a mk2 inhibitor
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2022020562A1 (en) 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Similar Documents

Publication Publication Date Title
JP2019194236A5 (enExample)
JP2018024670A5 (enExample)
JP2020515557A5 (enExample)
JP2022078315A5 (enExample)
JP2021020948A5 (enExample)
JP2018030858A5 (enExample)
JP2018521020A5 (enExample)
JP2009149903A5 (enExample)
JP2013532130A5 (enExample)
JP2019089762A5 (enExample)
JP2017186358A5 (enExample)
JP2019207442A5 (enExample)
JP2018150298A5 (enExample)
JP2017222697A5 (enExample)
JP2011518833A5 (enExample)
JP2018536572A5 (enExample)
JP2009535462A5 (enExample)
JP2010501534A5 (enExample)
JP2011527560A5 (enExample)
JP2012111758A5 (enExample)
JP2016153424A5 (enExample)
JP2012107057A5 (enExample)
JP2020513021A5 (enExample)
JP2014235432A5 (enExample)
JP2019124943A5 (enExample)